HCID 20639928, compound → HCID 20639782, compound

HRID 635632Notes

Reaction equation

HRID 635632 reaction equation
C([O:5][C:6]([CH2:8][CH2:9][C:10]([NH:12][C@H:13]([C:22]([NH:24][C@H:25]([C:35]([NH:37][C@H:38]([C:47]([NH:49][C@H:50]([C:55]([NH:57][C@H:58]([C:63]([NH:65][CH:66]([CH2:72][C:73]([F:76])([F:75])[F:74])[C:67](=[O:71])[C:68]([NH2:70])=[O:69])=[O:64])[CH2:59][CH:60]([CH3:62])[CH3:61])=[O:56])[C:51]([CH3:54])([CH3:53])[CH3:52])=[O:48])[CH2:39][C:40]1[CH:45]=[CH:44][CH:43]=[CH:42][C:41]=1[CH3:46])=[O:36])[CH2:26][CH2:27][C:28](=[O:34])[O:29]C(C)(C)C)=[O:23])[CH2:14][C:15](=[O:21])[O:16]C(C)(C)C)=[O:11])=[O:7])(C)(C)C>FC(F)(F)C(O)=O.C1(C)C=CC=CC=1>[C:6]([CH2:8][CH2:9][C:10]([NH:12][C@H:13]([C:22]([NH:24][C@H:25]([C:35]([NH:37][C@H:38]([C:47]([NH:49][C@H:50]([C:55]([NH:57][C@H:58]([C:63]([NH:65][CH:66]([CH2:72][C:73]([F:74])([F:76])[F:75])[C:67](=[O:71])[C:68]([NH2:70])=[O:69])=[O:64])[CH2:59][CH:60]([CH3:62])[CH3:61])=[O:56])[C:51]([CH3:52])([CH3:54])[CH3:53])=[O:48])[CH2:39][C:40]1[CH:45]=[CH:44][CH:43]=[CH:42][C:41]=1[CH3:46])=[O:36])[CH2:26][CH2:27][C:28](=[O:29])[OH:34])=[O:23])[CH2:14][C:15](=[O:16])[OH:21])=[O:11])([OH:7])=[O:5]

Participants

4

Reactant 1

HCID 20639928HCID 20639928, compound

Product 1

HCID 20639782HCID 20639782, compound

Reagents, catalysts & solvents 2

HCID 1140TolueneSolventHCID 6422Trifluoroacetic acidSolvent

Procedure

80 mg (0.074 mmol) of 3(RS)-[[N-[N-[N-[N-[N-[3-(tert-butoxycarbonyl)propionyl]-O-tert-butyl-L-αaspartyl]-O-tert-butyl-L-α-glutamyl]-2-methyl-L-phenylalanyl]-3-methyl-L-valyl]-L-leucyl]amino]-5,5,5-trifluoro-2-oxovaleramide were dissolved in 3 ml of trifluoroacetic acid and the solution was stirred at room temperature for 30 minutes. The solution was then diluted with 10 ml of toluene and the solvent was removed by evaporation. The residue was purified by reverse-phase high-pressure liquid chromatography on a Dynamax C18 column (5 micron, 300A, 21.4×50 mm). The elution gradient comprised 90% SSA 10% SSB to 95% SSB 5% SSA over 8.5 minutes (SSA is 0.1% trifluoroacetic acid in water; SSB is 0.1% trifluoroacetic acid in 70% acetonitrile and 30% water). After lyophilization overnight there were obtained 12 mg of 3(R or S)-[[N-[N-[N-[N-[N-(3-carboxypropionyl)-L-α-aspartyl]-L-α-glutamyl]-2-methyl-L-phenylalanyl]-3-methyl-L-valyl]-L-leucyl]amino]-5,5,5-trifluoro-2-oxo-valeramide (diastereoisomer A); MS: m/e 916.3 [M+H]+, which was eluted first, and 8 mg of 3(R or S)-[[N-[N-[N-[N-[N-(3-carboxypropionyl)-L-α-aspartyl]-L-α-glutamyl]-2-methyl-L-phenylalanyl]-3-methyl-L-valyl]-L-leucyl]amino]-5,5,5-trifluoro-2-oxo-valeramide (diastereoisomer B); MS: m/e 916.2 [M+H]+, which was eluted subsequently.

Workup

  1. customthe solvent was removed by evaporation
  2. customThe residue was purified by reverse-phase high-pressure liquid chromatography on a Dynamax C18 column (5 micron, 300A, 21.4×50 mm)
  3. customSSA over 8.5 minutes

Sources & evidence

ORD record
ord-c3d348836f5c468d8ba2a59dd89bbfef
Source dataset
uspto-grants-2001_02
Patent number
US06187905B1

Reaction notes

Loading…